6556-11-2
Chemical Structure
Inositol nicotinate
Synonym(s): Inositol niacinate; Hexanicit
- CAS No.: 6556-11-2
- Formula:C42H30N6O12
- Molecular Weight:810.72
IUPAC Name: (1R,2r,3S,4R,5s,6S)-cyclohexane-1,2,3,4,5,6-hexayl hexanicotinate
InChIKey: MFZCIDXOLLEMOO-GYSGTQPESA-N
SMILES: O=C(C1=CC=CN=C1)O[C@H]2[C@@H](OC(C3=CC=CN=C3)=O)[C@@H](OC(C4=CC=CN=C4)=O)[C@H](OC(C5=CC=CN=C5)=O)[C@@H](OC(C6=CC=CN=C6)=O)[C@@H]2OC(C7=CC=CN=C7)=O
Biological Activity: Inositol nicotinate (Hexanicit) has vasodilating effects and can be used in research on peripheral arterial disease, showing efficacy when taken orally. Inositol nicotinate does not significantly improve triglyceride levels in mice induced by biphenyl esters[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Inositol nicotinate | 98.05% | Inositol nicotinate (Hexanicit) has vasodilating effects and can be used in research on peripheral arterial disease, showing efficacy when taken orally. Inositol nicotinate does not significantly improve triglyceride levels in mice induced by biphenyl esters. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Inositol nicotinate (Standard) | 98.96% | Inositol nicotinate (Standard) is the analytical standard of Inositol nicotinate. This product is intended for research and analytical applications. Inositol nicotinate, with vasodilatory effect, is used in the study of Peripheral arterial disease (PAD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Si-Yuan Pan, et al.High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: animal models of acute hypertriglyceridemia. Acta Pharmacol Sin. 2006 Jun;27(6):673-8. [Content Brief]
- [2]. H Squires, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. NIHR Health Technology Assessment programme: Executive Summaries. [Content Brief]
